Biomea Fusion, Inc. · NASDAQ:BMEA
Biomea Fusion — Investor Presentation (February 2026)
37 slides from Biomea Fusion's investor presentation, Feb 25, 2026
Slide 1: Biomea Fusion Corporate Presentation 1st Quarter 2026
Exhibit 99.1 st 1 QUARTER 2026 Biomea Fusion Corporate Presentation 1
Slide 2: Legal disclaimer & forward-looking statements
Legal disclaimer & forward-looking statements Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future business and financial performance of Biomea Fusion, Inc. (the “Company”) and involve know
Slide 3: Transforming diabetes and obesity with novel oral medicines
Transforming diabetes and obesity with novel oral medicines Biomea Fusion founded in 2017 (public in 2021; NASDAQ: BMEA ) Clinical-stage company advancing two differentiated metabolic investigative programs ICOVAMENIB Potential first-in-class oral menin inhibitor - the control switch to beta cell re
Slide 4: Biomea Fusion pipeline – targeting diabetes & obesity
Biomea Fusion pipeline – targeting diabetes & obesity Biomea Fusion retains full worldwide rights across all programs Program Indications Pre-clinical Phase I Phase II Phase III Key Catalysts Phase II 26-week data Type 2 diabetes (study initiated) ICOVAMENIB COVALENT-211 (primary endpoint) Patients
Slide 5: Icovamenib: potential first-in-class menin inhibitor to restore functional beta-cells
ICOVAMENIB Severe insulin-deficient diabetes patients after 12-weeks of dosing Potential first-in-class menin inhibitor aimed to restore functional beta-cells Aims to serve a significant unmet need for millions of diabetes patients failing on standard of care Icovamenib is developed to: GLP-1 RA unc
Slide 6: Two transformative phase II trials ongoing
Two transformative phase II trials ongoing Near term readouts expected in 4Q 2026 ICOVAMENIB Two Phase II trials underway Phase IIa completed and proposed mechanism supported COVALENT-211 • Persistent 52-week HbA1c reduction Insulin-deficient T2D failing standard of care after 12 weeks of treatment
Slide 7: Diabetes patients are poorly controlled with over 7M US patients needing insulin
Diabetes patients are poorly controlled with over 7M US patients currently needing insulin as a last resort Icovamenib targets beta-cell restoration and may delay or prevent onset of end-stage disease 1 38M of people with diabetes will die from the disease 4 PEOPLE IN THE US WITH DIABETES The end-st
Slide 8: BMF-650 Oral GLP-1 RA developed for improved tolerability
BMF-650 Oral GLP-1 RA developed for improved patient friendly tolerability ~15% Body Weight Reduction Aims to serve a significant unmet need with millions of in 28-day Obese Monkey Study obese Americans dropping off the available GLP-1 1 RAs agents within the first year BMF-650 is developed to: Buil
Slide 9: Biology, mechanism of action & preclinical findings
ICOVAMENIB Biology, mechanism of action & preclinical findings
Slide 10: Icovamenib's mechanism of action
ICOVAMENIB | PRECLINICAL Icovamenib’s mechanism of action IMPROVED BETA CELL MASS & FUNCTION Induction of beta Increase in insulin cell proliferation Decrease in blood glucose Pancreatic islet Icovamenib promotes selective and partial reduction in menin levels Lowering menin levels releases the brea
Slide 11: Icovamenib increased beta cell quantity, function & GLP-1 receptor expression
ICOVAMENIB | PRECLINICAL Icovamenib increased beta cell quantity, function & GLP-1 receptor expression following a short treatment period Improved beta cell mass and function BUILDING OF THE ICOVAMENIB MATURATION OF BETA CELL POOL BETA CELL POOL Dosing Follow-up period Long-term follow-up 12 weeks a
Slide 12: Icovamenib downregulated menin and promoted beta cell proliferation in human islets
ICOVAMENIB | PRECLINICAL ICOVAMENIB | PRECLINICAL Icovamenib downregulated menin protein levels & promoted beta cell proliferation in ex vivo human islet cultures ICOVAMENIB CONDITIONALLY PROMOTED BETA CELL PROLIFERATION MENIN LEVELS DOWNREGULATED ONLY UNDER HYPERGLYCEMIC CONDITIONS Standard Glucose
Slide 13: Icovamenib enhanced GLP-1 receptor & insulin expression, synergy with semaglutide
ICOVAMENIB | PRECLINICAL ICOVAMENIB | PRECLINIAL Icovamenib enhanced GLP-1 receptor & insulin expression and demonstrated potential synergy in combination with semaglutide ex vivo Culture 7 days under glucotox conditions (8mM glucose) Cadaver derived • Gene expression & Protein analysis human islets
Slide 14: Icovamenib & low-dose semaglutide reduced food intake & body weight
ICOVAMENIB WITH GLP-1RA Combination treatment of icovamenib & low-dose semaglutide reduced food intake & body weight APPETITE SUPPRESSION BODY WEIGHT REDUCTION ❑ SUPERIOR APPETITE SUPPRESSION WITH ABOUT 10% GREATER BODY WEIGHT REDUCTION THAN LOW-DOSE SEMAGLUTIDE ALONE ❑ THE OBSERVED BODY WEIGHT REDU
Slide 15: Potential first-in-class oral menin inhibitor clinical study results
ICOVAMENIB Potential first-in-class oral menin inhibitor clinical study results
Slide 16: COVALENT-111 Baseline demographics & characteristics
ICOVAMENIB | COVALENT-111 Baseline demographics & characteristics Per Protocol Population* on 1 or More Antihyperglycemic Agents at Baseline (N=163) Arm C Arm A Arm B Combined Arms Combined Arms icovamenib Parameter icovamenib icovamenib (8 wks 100 mg QD then 4 icovamenib placebo (8 wks 100mg QD) (1
Slide 17: COVALENT-111 Change in HbA1c from baseline through week 52
ICOVAMENIB | COVALENT-111 Change in HbA1c from baseline through week 52 – all subtypes Across treatment durations (Arm A = 8 weeks 100 mg, Arm B = 12 weeks 100 mg, Arm C = 8 weeks 100 mg 4 weeks at 200 mg) per protocol participants taking one or more antihyperglycemic medications at baseline 0.2 TRE
Slide 18: COVALENT-111 Higher HbA1c reduction associated with higher exposure
ICOVAMENIB | COVALENT-111 Higher HbA1c reduction was associated with higher icovamenib exposure Week 52, All Dosing Arms (N=114), HbA1c Reduction vs. Icovamenib Exposure (Mean AUC) • Dosing timing relative to food will 184 ≥0.5% impact icovamenib’s pharmacokinetics (PK) 207 ≥1.0% • In a ‘Food Effect
Slide 19: 12 weeks of dosing delivered lasting benefit in severe insulin-deficient patients
ICOVAMENIB 12 weeks of dosing (arms B&C) delivered lasting benefit through 52 weeks for severe insulin-deficient diabetes patients 1.0 INITIAL TARGET TREATMENT OFF-TREATMENT POPULATION FOR ICOVAMENIB 0.5 0.3 Pooled Placebo (N=12) 0.1 icovamenib (N=10) 0.0 -0.3 -0.5 -0.5% threshold for clinical signi
Slide 20: Icovamenib increased C-peptide index in severe insulin-deficient patients
ICOVAMENIB Icovamenib increased insulin secretion as measured by C-peptide index in severe insulin-deficient patients (arms B&C) 1.6 TREATMENT OFF-TREATMENT Icovamenib (N=10) 1.5 Placebo (N=12) 1.4 1.3 24% 1.2 1.1 2% 1.0 0.9 0.8 0.7 0 12 52 Weeks 20 Data censored at onset of rescue medication, defin
Slide 21: Durable HbA1c reduction in patients on GLP-1 based therapy
ICOVAMENIB Patients on a GLP-1 based therapy at enrollment showed durable & clinically meaningful response in reduction of blood sugar (HbA1c) 1.5 TREATMENT OFF-TREATMENT 1.1 1.0 0.6 0.5 Pooled Placebo (N=4) 0.1 icovamenib (N=12) 0.0 -0.3 -0.5% threshold for clinical significance -0.5 CMS Clinical E
Slide 22: Icovamenib increased C-peptide index in GLP-1 RA treated patients
ICOVAMENIB Icovamenib increased insulin secretion as measured by C-peptide index in GLP-1 RA treated patients – 9 months post last dose 1.6 TREATMENT OFF-TREATMENT 35% 1.4 Icovamenib (N=11) Placebo (N=4) 1.2 -4% 1.0 0.8 0.6 0.4 0 12 52 Weeks 22 Data censored at onset of rescue medication, defined as
Slide 23: COVALENT-111 Favorable 52-week safety profile
ICOVAMENIB | COVALENT-111 Favorable 52-week safety profile Arm A Arm B Arm C Combined Arms Combined Arms Parameter icovamenib icovamenib icovamenib icovamenib placebo (N=67) (N=67) (N=67) (N=201) (N=66) Patients with ≥1 TEAE, N (%) 19 (28) 22 (33) 14 (21) 55 (27) 18 (27) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0
Slide 24: Key findings through week 52 after a short treatment course
ICOVAMENIB Key findings through week 52 after a short treatment course Menin Inhibition Durable Clinical Activity Durable Clinical Activity Potentially Leads to in T2D Not Controlled on Favorable Safety in Insulin Deficient T2D Increased Clinical Benefit GLP-1-based Therapies Profile Higher exposure
Slide 25: Potential first-in-class oral menin inhibitor Ongoing Phase II Studies
ICOVAMENIB Potential first-in-class oral menin inhibitor Ongoing Phase II Studies
Slide 26: Optimal dose, dose-duration, target population identified for phase IIb program
Optimal dose, dose-duration, target population identified for phase IIb program ICOVAMENIB Direct application in Phase II/IIb’s COVALENT-211 Phase IIa key derisking-insights Phase IIb trial in type 2 insulin deficient diabetes patients • Optimal dose selected failing standard of care • Adult partici
Slide 27: COVALENT-211 Phase II trial in T2D insulin deficient participants
ICOVAMENIB | COVALENT-211 A Phase II trial of icovamenib in T2D insulin deficient participants who are not achieving glycemic targets Objectives Endpoints Inclusion Criteria Objectives Endpoints Inclusion Criteria • Adult participants with Type 2 Diabetes who were • Mean change in HbA1c from baselin
Slide 28: COVALENT-212 Phase II trial in T2D on GLP-1-based therapy
ICOVAMENIB | COVALENT-212 Phase II trial of icovamenib in participants with T2D who are not achieving glycemic targets while using GLP-1-based therapy Objectives Endpoints Inclusion Criteria Objectives Endpoints Inclusion Criteria • Adult participants with T2D who are not achieving • Mean change in
Slide 29: BMF-650 oral GLP-1 receptor agonist for obesity
BMF-650 An investigational next-generation oral GLP-1 receptor agonist for obesity Preclinical results and clinical overview
Slide 30: BMF-650 Developed to deliver strong efficacy with improved oral tolerability
BMF-650 Developed to deliver strong efficacy with improved oral tolerability An Investigational Next-Generation Oral GLP-1 Receptor Agonist Greater therapeutic Proposed differentiated properties of BMF-650 window matters • Only 3 of 10 patients remain on GLP-1 therapy at one year due to tolerability
Slide 31: BMF-650 demonstrated robust, dose dependent weight loss in obese monkeys
BMF-650 | PRECLINICAL BMF-650 | PRECLINICAL BMF-650 demonstrated robust, dose dependent weight loss in obese monkeys Weight loss in cross-study comparison with CT-996 (Roche/Carmot), while not head-to-head appeared favorable BMF-650 up to ~15% body weight reduction after 28-days CT-996 body weight c
Slide 32: BMF-650 GLP-131 first-in-human study design
BMF-650 | GLP-131 A Randomized, Double-blind, Placebo-controlled, FIH Study of an Oral Non-peptide GLP-1 Receptor Agonist Part 1 is a single ascending dose (SAD) study and Part 2 is a multiple ascending dose (MAD) study. Single Ascending Dose (SAD) Multiple Ascending Dose (MAD) Safety and tolerabili
Slide 33: Biomea pipeline
Biomea pipeline Biomea Fusion retains full worldwide rights across all programs and is currently funded through major catalysts into 1Q 2027 PROGRAM INDICATION PHASE I PHASE II PHASE III UPCOMING MILESTONES Type 1 diabetes ICOVAMENIB 52-week follow-up data of those COVALENT-112 Potential first-in- P
Slide 34: Thank you
THANK YOU (NASDAQ: BMEA) For questions or inquiries, please reach out to Meichiel Weiss at ir@biomeafusion.com www.biomeafusion.com
Slide 35: Slowing the clock on diabetes
Slowing the clock on diabetes Turning a healthcare crisis into a huge opportunity The problem: Diabetes is a global healthcare crisis, with over 800 million people affected worldwide. The disease is expanding at an estimated ~4% annually. In the United States, one in every four healthcare dollars is
Slide 36: Key opinion leaders highlight icovamenib's potential to redefine diabetes care
Key opinion leaders highlight icovamenib’s potential to redefine diabetes care “Icovamenib's recent data has shown an “The icovamenib data looks exciting. “Great foray into precision medicine. We impressive restoration of beta cell The data presented today help to need to be addressing patients in a
Slide 37: Key opinion leaders highlight icovamenib's potential to redefine diabetes care
Key opinion leaders highlight icovamenib’s potential to redefine diabetes care “We do not have an agent today that “The icovamenib data are quite “Icovamenib is a very interesting addresses one of the root cause of interesting because of the continued molecule that acts quite differently than diabet
Biomea Fusion — Investor Presentation (February 2026) on 6ix